The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | MRD in myeloma: the patient perspective
Lanny Kirsch, MD, Adaptive Biotechnologies, Seattle, WA, talks on the patient perspective on measurable residual disease (MRD) in myeloma, talking on reports from patient advocacy groups. Dr Kirsch explains how knowing that a tool as sensitive as MRD is available can be of comfort to patients. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Lanny Kirsch, MD, is an employee and stock option holder in Adaptive Biotechnologies, Inc.
